Total Payments
$276,555
2024 Payments
$10,236
Companies
21
Transactions
287
Medicare Patients
1,036
Medicare Billing
$217,186
Payment Breakdown by Category
Other$161,904 (58.5%)
Consulting$74,101 (26.8%)
Travel$26,808 (9.7%)
Food & Beverage$8,285 (3.0%)
Research$5,445 (2.0%)
Education$11.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150,084 | 50 | 54.3% |
| Consulting Fee | $74,101 | 26 | 26.8% |
| Travel and Lodging | $26,808 | 81 | 9.7% |
| Honoraria | $11,820 | 4 | 4.3% |
| Food and Beverage | $8,285 | 121 | 3.0% |
| Unspecified | $5,445 | 4 | 2.0% |
| Education | $11.50 | 1 | 0.0% |
Payments by Type
General
$271,110
283 transactions
Research
$5,445
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $152,307 | 137 | $0 (2024) |
| PFIZER INC. | $33,128 | 31 | $0 (2024) |
| Genentech USA, Inc. | $25,355 | 26 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $15,449 | 15 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $11,298 | 16 | $0 (2020) |
| Eisai Inc. | $10,946 | 14 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $8,312 | 8 | $0 (2019) |
| GENZYME CORPORATION | $4,179 | 8 | $0 (2022) |
| Janssen Biotech, Inc. | $3,680 | 5 | $0 (2018) |
| Immunomedics, Inc. | $2,700 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,236 | 17 | Eisai Inc. ($5,464) |
| 2023 | $1,927 | 12 | Janssen Scientific Affairs, LLC ($825.00) |
| 2022 | $40,435 | 41 | Exelixis Inc. ($30,088) |
| 2021 | $27,139 | 20 | Exelixis Inc. ($20,895) |
| 2020 | $25,963 | 21 | Exelixis Inc. ($14,788) |
| 2019 | $47,370 | 37 | Exelixis Inc. ($27,302) |
| 2018 | $82,393 | 88 | Exelixis Inc. ($33,873) |
| 2017 | $41,092 | 51 | Exelixis Inc. ($22,891) |
All Payment Transactions
287 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,205.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $187.07 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $1,980.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/07/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $135.45 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $83.98 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $35.72 | General |
| Category: Oncology | ||||||
| 11/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $19.51 | General |
| Category: Oncology | ||||||
| 09/16/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $142.26 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $87.10 | General |
| Category: HORMONE THERAPY | ||||||
| 01/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $136.78 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 01/25/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $148.58 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 01/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $57.74 | General |
| Category: Oncology | ||||||
| 01/23/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 01/03/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,205.00 | General |
| Category: Oncology | ||||||
| 01/03/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $375.00 | General |
| Category: Oncology | ||||||
| 01/03/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $187.07 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 11/11/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $116.39 | General |
| Category: Oncology | ||||||
| 11/11/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $21.30 | General |
| Category: Oncology | ||||||
| 08/22/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Oncology | ||||||
| 06/05/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: Oncology | ||||||
| 06/04/2023 | Astellas Pharma Global Development | Xtandi (Drug) | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $162.17 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $111.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| SUNITINIB MALATE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor CPI therapy | Seattle Genetics, Inc. | $65.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 193 | 496 | $170,086 | $50,399 |
| 2022 | 4 | 271 | 635 | $221,722 | $64,396 |
| 2021 | 4 | 267 | 600 | $205,904 | $61,470 |
| 2020 | 6 | 305 | 550 | $172,920 | $40,921 |
Total Patients
1,036
Total Services
2,281
Medicare Billing
$217,186
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 155 | 429 | $147,576 | $43,283 | 29.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 43 | $10,750 | $4,048 | 37.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $11,760 | $3,068 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 199 | 542 | $186,448 | $54,731 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 49 | 49 | $24,010 | $6,407 | 26.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 32 | $8,000 | $2,271 | 28.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 12 | $3,264 | $986.27 | 30.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 177 | 471 | $162,024 | $49,369 | 30.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 48 | 48 | $23,520 | $6,221 | 26.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 59 | $14,750 | $4,836 | 32.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 21 | 22 | $5,610 | $1,043 | 18.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 141 | 342 | $117,648 | $27,039 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 78 | 113 | $28,815 | $6,047 | 21.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 46 | 46 | $22,540 | $5,826 | 25.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 17 | 22 | $1,606 | $882.09 | 54.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 14 | $1,596 | $864.29 | 54.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 11 | 13 | $715.00 | $262.93 | 36.8% |
About Dr. Michael Harrison, M.D
Dr. Michael Harrison, M.D is a Medical Oncology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2007. The National Provider Identifier (NPI) number assigned to this provider is 1760674535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Harrison, M.D has received a total of $276,555 in payments from pharmaceutical and medical device companies, with $10,236 received in 2024. These payments were reported across 287 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($150,084).
As a Medicare-enrolled provider, Harrison has provided services to 1,036 Medicare beneficiaries, totaling 2,281 services with total Medicare billing of $217,186. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Durham, NC
- Active Since 08/15/2007
- Last Updated 05/03/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1760674535
Products in Payments
- Cabometyx (Drug) $121,608
- CABOMETYX (Drug) $23,365
- TECENTRIQ (Biological) $16,674
- IMFINZI (Drug) $15,449
- Lenvima (Drug) $10,946
- INLYTA (Drug) $10,114
- Xofigo (Drug) $8,301
- ORGOVYX (Drug) $4,387
- OPDIVO (Biological) $3,840
- Trodelvy (Drug) $2,700
- FOTIVDA (Drug) $2,482
- ILLUCCIX (Drug) $2,149
- PADCEV (Biological) $1,785
- SUTENT (Drug) $1,062
- ERLEADA (Drug) $825.00
- NO PRODUCT DISCUSSED (Drug) $784.79
- XTANDI (Drug) $650.29
- PLUVICTO (Drug) $195.74
- JEVTANA (Drug) $125.04
- PROVENGE (Drug) $123.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Durham
Dr. Thomas Leblanc, Md, Ma, MD, MA
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Andrew Armstrong, Md, MD
Medical Oncology — Payments: $486,009
Medical Oncology $486,009
Neal Ready, Md, MD
Medical Oncology — Payments: $383,286
Medical Oncology $383,286
Nelson Chao, Md, MD
Medical Oncology — Payments: $79,858
Medical Oncology $79,858
Dr. Sundhar Ramalingam, M.d, M.D
Medical Oncology — Payments: $68,550
Medical Oncology $68,550
Dr. Gerard Blobe, M.d, M.D
Medical Oncology — Payments: $55,242
Medical Oncology $55,242